홈 > 사업단소개 > 오시는길
박은석
신범수 윤유석 정성훈
 
Name Youn, Yu Seok
Affiliation(department)
College of Pharmacy, Pusan National University
Position Assistant professor
E-mail ysyoun@pusan.ac.kr
Major field of study Pharmaceutics, Drug Delivery System
Role in the project
Co-researcher
Preformulation design
Platform development for basic formulation design
Education
1995.03 - 1999.02 B.S. College of Pharmacy, Sungkyunkwan University
1999.03 - 2001.02
M.S. College of Pharmacy, Sungkyunkwan University
2001.03 - 2004.02 Ph.D. Dept. of Manufacturing Pharmacy, College of Pharmacy, Sungkyunkwan University
Professional Experience
2004.03 - 2006.06 Post-doctoral research fellow, Sungkyunkwan University, Korea
2006.07 - 2007.08
Post-doctoral fellow, Department of pharmaceutics and pharmaceutical chemistry, University of Utah
2007 - present
Assistant professor, Dept. of manufacturing pharmacy, College of pharmacy, Pusan National University
2008.01- 2008.02
Visiting professor, Dept. of pharmaceutics and pharmaceutical chemistry, University of Utah
2008.01 - present
Secretary, Korean Society of Pharmaceutical Sciences and Technology
Publications:selected papers from 42 papers (SCI)
[1] Kim, T.H. Kim, K. Ma, E.S. Lee, D. Kim, K.T. Oh, D.H. Lee, K.C. Lee, Y.S. Youn. Synthesis and evaluation of human serum albumin-modified exendin-4 conjugate via heterobifunctional polyethylene glycol linkage with protracted hypoglycemic efficacy, Bioconjug. Chem. 21(8), 15131519 (2010).
[2] S.Y. Chae, T.H .Kim, K. Park, C.H. Jin, S. Son, S. Lee, Y.S. Youn, K. Kim, D.G. Jo, I.C. Kwon, X. Chen, K.C. Lee. Improved antitumor activity and tumor targeting of NH2-terminal-specific PEGylated tumor necrosis factor-related apoptosis-inducing ligand, Mol. Cancer Ther. 9(6), 1719-1729 (2010)
[3] N.M. Oh, K.T. Oh, H.J. Baik, B.R. Lee, A.H. Lee, Y.S. Youn, E.S. Lee, A self-organized 3-diethylaminopropyl-bearing glycol chitosan nanogel for tumor acidic pH targeting: in vitro evaluation, Colloids Surf B Biointerfaces 78(1), 120-126 (2010)
[4] B.R. Lee, K.T. Oh, H.J. Baik, Y.S. Youn, E.S. Lee, A charge-switched nano-sized polymeric carrier for protein delivery, Int. J. Pharm. 392(1-2), 78-82 (2010)
[5] S.Y. Chae, C-H. Jin, J.H. Shin, S. Son, T.H. Kim, S. Lee, Y.S. Youn, Y. Byun, Lee, K.C. Lee, Biochemical, pharmaceutical and therapeutic properties of long-acting lithocholic acid derivatized exendin-4 analogs, J. Control. Release, 133(3), 172-177 (2009).
[6] K.T. Oh, H.J. Baik, A.H. Lee, Y.T. Oh, Y.S. Youn, E.S. Lee. The Reversal of Drug-Resistance in Tumors Using a Drug-Carrying Nanoparticular System, Int. J. Mol. Sci. 10, 3776-3792 (2009).
[7] K.C. Lee, Y.G. Chun, I. Kim, B.S. Shin, E.-S. Park, S.D. Yoo, Y.S. Youn. Development and Validation of a Reversed-Phase Fluorescence HPLC Method for Determination of Bucillamine in Human Plasma Using Pre-column Derivatization with Monobromobimane, J. Chromatogr. B 877(22) 2130-2134 (2009).
[8] C.H. Jin, S.Y. Chae, S. Son, T.H. Kim, K.A. Um, Y.S. Youn, S. Lee, K.C. Lee. A new orally available glucagon-like peptide-1 receptor agonist, biotinylated exendin-4, displays improved hypoglycemic effects in db/db mice, J. Control. Release, 133(3)172-177 (2009).
[9] K.C. Lee, S.Y. Chae, T.H. Kim, S. Lee, E.S. Lee, and Y.S. Youn. Intrapulmonary Potential of Polyethylene Glycol-Modified Glucagon-Like Peptide-1s as a Type 2 Anti-Diabetic Agent, Regul. Pept., 152(1-3), 101-107 (2009).
[10] M. Cetin, Y.S. Youn, Y. Capan, K.C. Lee. Preparation and characterization of salmon calcitonin-biotin conjugates, AAPS PharmSciTech, 9(4) 1191-1197 (2008).
[11] S.Y. Chae, Y.G. Chun, S. Lee, C.-H. Jin, E.S. Lee, K.C. Lee, Y.S. Youn. Pharmacokinetic and Pharmacodynamic Evaluation of Site-Specific PEGylated Glucagon-Like Peptide-1 Analogs as Flexible Postprandial-Glucose Controllers, J. Pharm. Sci., 98(4) 1556-1567 (2009)
[12] E.S. Lee and Y.S. Youn, Poly(benzyl-L-histidine)-b-Poly(ethylene glycol) Micelle Engineered for Tumor Acidic pH-Targeting, Bull. Korean Chem. Soc. 29(8), 1-6 (2008).
[13] S.Y. Chae, C-H. Jin, H.J. Shin, Y.S. Youn, S. Lee, and K.C. Lee. Preparation, characterization, and application of biotinylated and biotin-PEGylated glucagon-like peptide-1 analogues for enhanced oral delivery, Bioconjug. Chem., 19(1), 34-341 (2008).
[14] E.S. Lee, D. Kim, Y.S. Youn, K.T. Oh, Y.H. Bae, A virus-mimetic nanogel vehicle, Angewandte Chemie Int. Ed. 47(13), 1-5 (2008).
[15] Y.S. Youn, S.Y. Chae, S. Lee, M.J. Kwon, H.J. Shin, and K.C. Lee, Improved peroral delivery of glucagon-like peptide-1 by site-specific biotin modification: Design, preparation, and biological evaluation, Eur. J. Pharm. Biopharm., 68(3), 667-675 (2008).
[16] Y.S. Youn, M.J. Kwon, D.H. Na, S.Y. Chae, S. Lee, and K.C. Lee, Improved intrapulmonary delivery of site-specific PEGylated salmon calcitonin: Optimization by PEG size selection, J. Control. Release, 125(1), 68-75 (2008).
[17] Y.S. Youn, J.E. Jeon, S.Y. Chae, S. Lee, and K.C. Lee. PEGylation improves the hypoglycemic efficacy of intranasally administered glucagon-like peptide-1 in type 2 diabetic db/db mice, Diabetes. Obes. Metab., 10, 343-346 (2008).
[18] A. Taluja, Y.S. Youn, and Y.H. Bae, Novel approaches in microparticulate PLGA delivery systems encapsulating proteins, J. Mater. Chem., 17, 4002-4014 (2007).
[19] E.S. Lee, K.T. Oh, D. Kim, Y.S. Youn, and Y.H. Bae, Tumor pH-responsive flower-like micelles of poly(l-lactic acid)-b-poly(ethylene glycol)-b-poly(l-histidine), J. Control. Release, 123(1), 19-26 (2007).
[20] D.W. Jeong, Y.H. Kim, H.Y. Ji, Y.S. Youn, K.C.Lee, H.S. Lee, Analysis of carvedilol in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry, J. Pharmaceut. Biomed. Analysis, 44(2), 547-552 (2007).
[21] Y.S. Youn, M.J. Shin, S.Y. Chae, C-H. Jin, T.H. Kim, and K.C. Lee, Biological and physiochemical evaluation of the conformational stability of tumor necrosis factor-related apoptosis including ligand (TRAIL), Biotechnol. Lett., 29(5), 713-721 (2007).
[22] Y.S. Youn and K.C. Lee, Site-Specific PEGylation for High-Yield Preparation of Lys21-Amine PEGylated Growth Hormone-Releasing Factor (GRF) (1-29) using a GRF(1-29) Derivative FMOC-Protected at Tyr1 and Lys12, Bioconjug. Chem., 18(2), 500-506 (2007).
[23] Shin B.S., Choi J.W., Balsathar J.P., Hong D.K., Kim J.J., Yoo S.D., Determination of roxatidine in human plasma by liquid chromatography/electrospray mass spectrometry and application to a clinical pharmacokinetic study. Rapid Communications in Mass Spectrometry. 21:329-335 (2007)
[24] Y.S. Youn, D.H. Na, and K.C. Lee, High-yield production of biologically active mono-PEGylated salmon calcitonin conjugate by site-specific PEGylation, J. Control. Release, 117(3), 371-379 (2007).
[25] D.H. Na, Y.S. Youn, I.B. Lee, E.J. Park, C.J. Park, and K.C. Lee, Effect of molecular size of PEGylated recombinant human epidermal growth factor on the biological activity and stability in rat wound tissue, Pharm. Dev. Technol., 11(4), 513-519 (2006).
[26] Y.S. Youn, S.Y. Chae, S. Lee, J.E. Jeon, H.G. Shin, and K.C. Lee, Evaluation of therapeutic potentials of site-specific PEGylated glucagon-like peptide-1 isomers as a type 2 anti-diabetic treatment: Insulinotropic activity, glucose-stabilizing capability, and proteolytic stability, Biochem. Pharmacol., 73(1), 84-93 (2007).
[27] H.Y. Ji, D.W. Jeong, Y.H. Kim, H-H. Kim, Y-S. Yoon, K.C. Lee, H.S. Lee, Determination of gabapentin in human plasma using hydrophilic interaction liquid chromatography with tandem mass spectrometry, Rapid Commun. Mass Spectrom., 20(14), 2127-2132 (2006).
[28] Y.S. Youn, J.Y. Jung, S.H. Oh, S.D. Yoo, and K.C. Lee, Improved intestinal delivery of salmon calcitonin by Lys18-amine specific PEGylation: Stability, permeability, pharmacokinetic behavior and in vivo hypocalcemic efficacy, J. Control. Release, 114(3), 334-342 (2006).
[29] . Lee, Y.S. Youn, S-H. Lee, Y. Byun, and K.C. Lee, PEGylated glucagon-like peptide-1 displays preserved effects on insulin release in isolated pancreatic islets and improved biological activity in db/db mice, Diabetologia, 49(7), 1608-1611 (2006).
[30] Y.W. Jo, Y.S. Youn, S.H. Lee, B.M. Kim, S.H. Kang, M. Yoo, E.C., Choi, and K.C. Lee, Long-acting interferon-α 2a modified with a trimer-structured polyethylene glycol: Preparation, in vitro bioactivity, in vivo stability and pharmacokinetics, Int. J. Pharm., 309(1), 87-93 (2006).
[31] B.S. Shin, C.H. Kim, Y.S. Jun, E.H. Park, M-W. Hur, K.C. Lee, Y.S. Yoon, M.-Y. Lee, and S.D. Yoo. Dose-linear pharmacokinetics, tissue distribution, and excretion of a recombinant fusion protein 125I-GST-TatdMt possessing potent anti-obesity activity, Regul. Pept., 129(1), 25-30 (2005).
[32] S. Mansoor, Y.S. Youn, and K.C. Lee, Oral delivery of mono-PEGylated sCT (Lys18) in rats: regional difference in stability and hypocalcemic effect, Pharm. Dev. Tech., 10(3), 389-396 (2005).
[33] Y.S. Youn, D.H. Na, S.D. Yoo, S-C. Song, and K.C. Lee, Carbohydrate-specifically polyethylene glycol-modified ricin A-chain with improved therapeutic potential, Int. J. Biochem. Cell Biol., 37(7), 1525-1533 (2005).
[34] S.H. Lee, S. Lee, Y.S. Youn, D.H. Na, S.Y. Chae, Y. Byun, and K.C. Lee, Synthesis, characterization, and pharmacokinetic studies of PEGylated glucagon-like peptide-1, Bioconjug. Chem., 16(2), 377-382 (2005).
[35] Y.S. Youn, D.H. Na, S.D. Yoo, S-C. Song, and K.C. Lee, Chromatographic separation and mass spectrometric identification of positional isomers of polyethylene glycol-modified growth hormone-releasing factor (1-29), J. Chromatogr. A., 1061(1), 45-49 (2004).
[36] D.H. Na, Y.S. Youn, and K.C. Lee, Matrix-assisted laser desorption/ionization time-of-flight mass spectrometry for monitoring and optimization of site-specific PEGylation of ricin A-chain, Rapid Commun. Mass Spectrom., 18(18), 2185-2189 (2004).
[37] D.H. Na, C.K. Cho, Y.S. Youn, Y-J Choi, K.R. Lee, S.D. Yoo, and K.C. Lee, Capillary electrophoresis to characterize ricin and its subunits with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, Toxicon, 43(3), 329-335 (2004).
[38] D.H. Na, E.J. Park, Y.S. Youn, B.W. Moon, Y.W. Jo, S.H. Lee, W.B. Kim, Y. Sohn, and K.C. Lee, Sodium dodecyl sulfate-capillary gel electrophoresis of polyethylene glycolylated interferon alpha, Electrophoresis, 25(3), 476-479 (2004).
[39] D.H. Na, Y.S. Youn, E.J. Park, J.M. Lee, O.R. Cho, K.R. Lee, S.D. Lee, S.D. Yoo, P.P. DeLuca, and K.C. Lee, Stability of PEGylated salmon calcitonin in nasal mucosa, J. Pharm. Sci., 93(2), 256-261 (2004).
[40] K.C. Lee, M-O. Park, D.H. Na, Y.S. Youn, S.D. Lee, S.D. Yoo, H.S. Lee, and P.P. DeLuca, Intranasal delivery of PEGylated salmon calcitonins: Hypocalcemic effects in rats, Calcif. Tissue Int., 73(6), 545-549 (2003).
[41] D.H. Na, Y.S. Youn, S.D. Lee, M-W. Son, W-B. Kim, P.P. DeLuca, and K.C. Lee, Monitoring of peptide acylation inside degrading PLGA microspheres by capillary electrophoresis and MALDI-TOF mass spectrometry, J. Control. Rel., 92(3), 291-299 (2003).
[42] D.H. Na, Y.S. Youn, and K.C. Lee, Optimization of the PEGylation process of a peptide by monitoring with matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, Rapid Commun. Mass Spectrom., 17(19), 2241-2244 (2003).
[43] S.J. Choi, S.B. Kim, H-Y. Lee, D.H. Na, Y.S. Yoon, S.S. Lee, J.H. Kim, K.C. Lee, and H.S. Lee, Column-switching high-performance liquid chromatographic determination of clarithromycin in human plasma with electrochemical detection, Talanta, 54(2), 377-382 (2001).